Physician profile
Robert E Holland
NPI 1457494130
$7,409.33
in general payments reported to CMS, 2019-2025
26 companies · $1,659 in 2025
The $1,659 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $676 · 2020: $434 · 2021: $742 · 2022: $643 · 2023: $1,374 · 2024: $1,880 · 2025: $1,659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,907 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,906.67 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,050.41 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,219.35 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Alkermes, INC. | $724.80 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Takeda Pharmaceuticals U.S.A., INC. | $517.72 | 2023-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $466.76 | 2019-2025 | Invega Sustenna, Spravato |
| Allergan, INC. | $455.01 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $383.81 | 2019-2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $318.76 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $180.03 | 2023-2024 | Auvelity |
| Bausch Health US, LLC | $159.61 | 2020-2024 | Wellbutrin, Aplenzin |
| E.R. Squibb & Sons, L.L.C. | $130.00 | 2025 | Cobenfy |
| Corium, LLC | $106.62 | 2022-2023 | Azstarys |
| Lundbeck LLC | $102.50 | 2019-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $94.68 | 2023-2024 | Quviviq |
| Almatica Pharma LLC | $86.61 | 2021-2024 | Loreev Xr, Gralise |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $86.28 | 2019-2020 | |
| Tris Pharma INC | $62.58 | 2022-2023 | Dyanavel Xr |
| Neos Therapeutics, LP | $47.68 | 2023-2025 | Adzenys Xr-Odt |
| Teva Pharmaceuticals USA, INC. | $44.90 | 2019-2024 | Uzedy |
| Ironshore Pharmaceuticals INC. | $39.87 | 2019-2022 | |
| Eisai INC. | $36.69 | 2020-2021 | |
| Noven Therapeutics, LLC | $24.79 | 2024 | Secuado, Xelstrym |
| Vertical Pharmaceuticals, LLC | $20.86 | 2019 | |
| Supernus Pharmaceuticals, INC. | $17.49 | 2021 | |
| Uswm, LLC | $17.17 | 2021 | |
| Orexo US, INC. | $14.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Holland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.